Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264882 | 0.90 | MET (0.57) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21322333 | 0.90 | MET (0.57) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21322099 | 0.86 | MET (0.57) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL23714116 | 0.84 | MET (0.54) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21264609 | 0.83 | MET (0.55) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21322263 | 0.83 | MET (0.55) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21264884 | 0.83 | MET (0.55) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21264730 | 0.81 | MET (0.52) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21322097 | 0.81 | MET (0.52) | METGPR119SLC2A1CHEK2ALOX5AP | |
| SCHEMBL21264736 | 0.81 | MET (0.80) | METGPR119SLC2A1CHEK2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501443-B2 | Pyridone compound as c-met inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | US | disclosed |
| EP-3533787-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | Fujian Cosunter Pharmaceutical Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | MET, PDXK, RET | MET 1/4885GPR119 688/4885SLC2A1 1585/4885 |
| US-10501443-B2 | Pyridone compound as c-met inhibitor | MET, PDXK, RET | MET 1/4885GPR119 688/4885SLC2A1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.